AbbVie (ABBV) Gains But Lags Market: What You Should Know
AbbVie (ABBV) closed at $113 in the latest trading session, marking a +0.02% move from the prior day. This change lagged the S&P 500's 0.23% gain on the day.
Coming into today, shares of the drugmaker had lost 0.19% in the past month. In that same time, the Medical sector gained 3.46%, while the S&P 500 gained 2.34%.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. On that day, ABBV is projected to report earnings of $3.09 per share, which would represent year-over-year growth of 32.05%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $13.64 billion, up 30.88% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $12.60 per share and revenue of $55.93 billion. These results would represent year-over-year changes of +19.32% and +22.12%, respectively.
Investors might also notice recent changes to analyst estimates for ABBV. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABBV currently has a Zacks Rank of #3 (Hold).
Digging into valuation, ABBV currently has a Forward P/E ratio of 8.97. This represents a discount compared to its industry's average Forward P/E of 14.7.
It is also worth noting that ABBV currently has a PEG ratio of 1.7. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABBV's industry had an average PEG ratio of 2.13 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 185, putting it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
